Fate Therapeutics (FATE)
(Delayed Data from NSDQ)
$3.87 USD
-0.43 (-10.00%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $3.86 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
FATE 3.87 -0.43(-10.00%)
Will FATE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for FATE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FATE
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
FATE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
Novartis (NVS) to Report Q1 Earnings: What to Expect?
What's in Store for Biogen (BIIB) This Earnings Season?
Other News for FATE
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Danaher (DHR) and Roche Holding AG (OtherRHHVF)
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Fly Intel: After-Hours Movers
Fate Therapeutics files to sell 3.64M shares for holders
Fate Therapeutics files to sell 3.64M shares of common stock for holders